• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Abbott Launches New Options for People with Cataracts in the United States

The U.S. FDA Approves Two New TECNIS® Multifocal Intraocular Lenses, Allowing People With Cataracts To Choose The Best Option For Their Lifestyle

- Cataract surgery is one of the most common procedures in the United States


News provided by

Abbott

Jan 30, 2015, 09:00 ET

Share this article

Share this article


ABBOTT PARK, Ill., Jan. 30, 2015 /PRNewswire/ -- Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States. The new TECNIS® Multifocal IOLs, developed by Abbott (NYSE: ABT), provide people with cataracts options to have a full range of near, intermediate and distance vision, while customizing their treatment based on their personal vision needs and lifestyle.

Continue Reading
The new TECNIS(R) Multifocal IOLs provide people with cataracts options to customize their treatment based on their personal vision needs and lifestyle.
The new TECNIS(R) Multifocal IOLs provide people with cataracts options to customize their treatment based on their personal vision needs and lifestyle.
Abbott seeing eye to eye infographic
Abbott seeing eye to eye infographic
Abbott Eye info graphic
Abbott Eye info graphic

Cataract surgery is one of the most common and safest procedures in the United States, with more than three million surgeries done each year. That number is expected to grow as the population gets older, and as some people choose to have cataract surgery sooner in life, given new technologies becoming available that can significantly improve vision.1

"Restoring or improving sight can make a huge impact on how people live their lives, which is why Abbott is continually investing in the research and development of advanced treatments to help people see their very best," said Murthy Simhambhatla, senior vice president, Medical Optics, Abbott. "We are pleased to offer the new TECNIS Multifocal IOLs for people with cataracts who want a full range of vision without having to wear eyeglasses, and who also want high-quality vision at a specific distance that is suited to their lifestyle."

An IOL is an artificial lens placed in a person's eye to restore vision after a cataract has been removed. While traditional monofocal IOLs are designed to restore far or distance vision, multifocal IOLs provide quality vision at multiple distances and reduce or eliminate the need for glasses.

The new lenses approved by the U.S. Food and Drug Administration are known as TECNIS Multifocal +2.75D and +3.25D IOLs. Along with the available TECNIS Multifocal +4.0D IOL, all of the TECNIS Multifocal IOLs provide excellent vision at near, intermediate and far distances, while each "lens power" version provides enhanced vision at a distinct distance.

The TECNIS Multifocal +4.0D is suited for people favoring near vision-related activities, such as reading a book. The TECNIS Multifocal +3.25D IOL is suited for people who favor activities at longer reading distances, such as reading a hand-held device like a tablet. The TECNIS Multifocal +2.75D IOL is suited for people who favor activities done with intermediate vision, such as reading labels while grocery shopping.

"My patients are extremely satisfied with the new TECNIS Multifocal lenses," said Dr. Kerry Assil, medical director of the Assil Eye Institute in Los Angeles. "Many of them are able to read easily, not only up close, but at intermediate distance as well, and in all lighting conditions. This improved vision following cataract surgery helps people live the active lives they want."

The TECNIS Multifocal IOLs have been well-studied. The FDA approval of the new TECNIS Multifocal +2.75D and +3.25D IOLS is based on a study of 445 people with cataracts. The results showed:

  • More than 80 percent of people reported being able to function comfortably without glasses at all distances
  • 93 percent of patients reported they would have the same IOL implanted again
  • Patients had a mean visual acuity of 20/25 in both eyes at near distances (uncorrected, or without glasses or contact lenses)
  • Patients had a mean visual acuity of 20/20 in both eyes at far distances (uncorrected)
  • Good vision was maintained in low lighting conditions

About Abbott:
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 77,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

Important indications and safety information - TECNIS Multifocal 1-Piece IOLs (for prescription only)

ATTENTION: Please see Directions for Use for a complete list of important indications, warnings, precautions, and adverse events.

INDICATIONS: The TECNIS Multifocal 1-Piece intraocular lenses, Models ZKB00 (+2.75 D) and ZLB00 (+3.25 D), are indicated for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire near, intermediate, and distance vision with increased spectacle independence. The intraocular lenses are intended to be placed in the capsular bag.

IMPORTANT SAFETY INFORMATION: Patients may experience possible contrast sensitivity reduction and increases in visual disturbances that may affect their ability to drive at night or in poor visibility conditions. Healthcare professionals should weigh the potential risk/benefit ratio for patients with conditions that could be exacerbated or may interfere with diagnosis or treatment. Secondary glaucoma has been reported occasionally in patients with previously controlled glaucoma who received lens implants. Multifocal IOL implants may be inadvisable in patients with conditions such macular degeneration, retinal pigment epithelium changes, and glaucoma. In rare cases, severe incidents of halos and/or glare may result in the multifocal IOL being explanted and replaced with another type of IOL.

1. 2014 Comprehensive Report on the Global IOL Market, Market Scope®, LLC

Photo - http://photos.prnewswire.com/prnh/20150129/172399
Photo - http://photos.prnewswire.com/prnh/20150129/172400-INFO
Photo - http://photos.prnewswire.com/prnh/20150129/172401-INFO

SOURCE Abbott

Related Links

http://www.abbott.com

Modal title

Also from this source

Abbott recebe autorização da Anvisa para Ultreon™, tecnologia de imagem que usa inteligência artificial para artérias coronárias

Abbott recebe autorização da Anvisa para Ultreon™, tecnologia de imagem que usa inteligência artificial para artérias coronárias


FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Household, Consumer & Cosmetics
  • Medical Pharmaceuticals
  • Retail
  • Pharmaceuticals

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.